Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) Director Purchases $32,500.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) Director Richard C. Pfenniger, Jr. purchased 25,000 shares of the stock in a transaction dated Monday, November 13th. The stock was purchased at an average price of $1.30 per share, with a total value of $32,500.00. Following the completion of the acquisition, the director now directly owns 300,000 shares in the company, valued at approximately $390,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OPKO Health Stock Performance

OPK stock opened at $1.42 on Thursday. OPKO Health, Inc. has a 1 year low of $1.00 and a 1 year high of $2.24. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -5.26 and a beta of 1.84. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.44 and a current ratio of 1.78. The stock’s fifty day moving average is $1.45 and its two-hundred day moving average is $1.65.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). OPKO Health had a negative net margin of 23.94% and a negative return on equity of 13.63%. The firm had revenue of $178.60 million for the quarter, compared to analyst estimates of $174.78 million. During the same period in the previous year, the firm earned ($0.11) earnings per share. The company’s revenue for the quarter was down .6% on a year-over-year basis. On average, research analysts predict that OPKO Health, Inc. will post -0.24 EPS for the current year.

Analyst Upgrades and Downgrades

OPK has been the subject of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday, August 7th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Piper Sandler increased their price objective on shares of OPKO Health from $4.00 to $5.00 in a research note on Monday, August 7th.

Hedge Funds Weigh In On OPKO Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its position in OPKO Health by 425.4% in the 1st quarter. Nisa Investment Advisors LLC now owns 17,390 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 14,080 shares during the period. Caprock Group LLC bought a new position in shares of OPKO Health in the first quarter worth $30,000. Capital Square LLC acquired a new position in shares of OPKO Health during the second quarter valued at $31,000. SlateStone Wealth LLC bought a new stake in shares of OPKO Health during the second quarter valued at about $34,000. Finally, Oak Thistle LLC acquired a new stake in OPKO Health in the second quarter worth about $36,000. 22.03% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.